Difference between revisions of "Team:HZAU-China/Collaborations"

 
(31 intermediate revisions by 5 users not shown)
Line 91: Line 91:
 
             z-index: 1;
 
             z-index: 1;
 
             background-color: #EEEEEE;
 
             background-color: #EEEEEE;
−
            opacity: 0.96;
 
−
            filter: alpha(opacity=96);
 
 
             box-shadow: 0 5px 15px #CCCCCC;
 
             box-shadow: 0 5px 15px #CCCCCC;
 
             display: none;
 
             display: none;
Line 134: Line 132:
 
             color: #ffffff;
 
             color: #ffffff;
 
             font-size: 16px !important;
 
             font-size: 16px !important;
 +
        }
 +
 +
        .daohang .xsjPic {
 +
            display: inline-block;
 +
            width: 10px;
 +
            height: 10px;
 +
            vertical-align: middle;
 +
            background-size: 100% 100%;
 +
            background-image: url("https://static.igem.org/mediawiki/2018/6/63/T--HZAU-China--xsj.svg")
 
         }
 
         }
  
Line 143: Line 150:
 
             background-size: 100% 100%;
 
             background-size: 100% 100%;
 
             background-image: url("https://static.igem.org/mediawiki/2018/8/8d/T--HZAU-China--xjt.svg")
 
             background-image: url("https://static.igem.org/mediawiki/2018/8/8d/T--HZAU-China--xjt.svg")
 +
        }
 +
 +
        .daohang a:hover span {
 +
            transform: rotateY(180deg);
 +
            -webkit-transform: rotateY(180deg);
 +
            -moz-transform: rotateY(180deg);
 +
            -o-transform: rotateY(180deg);
 +
            -ms-transform: rotateY(180deg);
 +
            transition: all 0.5s ease-in-out;
 +
            -webkit-transition: all 0.5s ease-in-out;
 +
            -moz-transition: all 0.5s ease-in-out;
 +
            -o-transition: all 0.5s ease-in-out;
 
         }
 
         }
  
Line 217: Line 236:
 
         }
 
         }
  
−
         @media screen and (max-width: 1000px) {
+
         @media screen and (max-width: 1200px) {
 
             .logo-daohang {
 
             .logo-daohang {
−
                 left: 5%;
+
                 left: 3%;
−
            }
+
−
 
+
−
            .daohang .caidan {
+
−
                right: 0;
+
 
             }
 
             }
  
 
             .daohangyi {
 
             .daohangyi {
−
                 font-size: 14px;
+
                 font-size: 12px;
 
             }
 
             }
 
         }
 
         }
Line 234: Line 249:
  
 
             .daohang .caidan {
 
             .daohang .caidan {
 +
                right: 0;
 
                 width: 100%;
 
                 width: 100%;
 
             }
 
             }
Line 251: Line 267:
 
             .daohangyi img {
 
             .daohangyi img {
 
                 display: none;
 
                 display: none;
 +
            }
 +
 +
            .daohang .longName .item:before {
 +
                width: 150px;
 +
                left: 20px;
 +
            }
 +
 +
            .daohang .longName .item:hover:after {
 +
                width: 150px;
 +
                left: 20px;
 
             }
 
             }
 
         }
 
         }
Line 274: Line 300:
 
             width: 80%;
 
             width: 80%;
 
             /* height: auto; */
 
             /* height: auto; */
−
             margin: 20px 20px 0 0;
+
             margin: 20px 40px 0 0;
 
             /* right: 2%; */
 
             /* right: 2%; */
 
             /* top: 90px; */
 
             /* top: 90px; */
−
             padding: 20px 3%;
+
             padding: 50px 3%;
 
             float: right;
 
             float: right;
 
             /* position: relative; */
 
             /* position: relative; */
Line 290: Line 316:
  
 
         .cebian {
 
         .cebian {
−
             width: 15%;
+
             width: 200px;
 
             /* height: 80vh; */
 
             /* height: 80vh; */
 
             float: left;
 
             float: left;
Line 299: Line 325:
 
             /* border:2px solid black */
 
             /* border:2px solid black */
 
             /* background-color: #323643 */
 
             /* background-color: #323643 */
 +
        }
 +
 +
        .zhengwen p{
 +
            text-align: justify !important;
 +
            font-family:  'Times New Roman',Helvetica,'Open Sans',  Arial, sans-serif !important;
 +
            color: #3B3B3B;
 +
            font-size: 26px !important;
 +
            padding-right: 20px;
 
         }
 
         }
  
Line 309: Line 343:
  
 
         .h1 {
 
         .h1 {
−
            height: 100px;
+
             line-height: 55px;
−
             line-height: 100px;
+
 
             font-weight: bold;
 
             font-weight: bold;
 +
            height:auto;
 
             font-family: 'Product Sans', sans-serif;
 
             font-family: 'Product Sans', sans-serif;
−
             font-size: 50px;
+
             font-size: 40px;
−
             color: black;
+
             color: #3B3B3B;
−
             border-bottom: 3px solid black;
+
             border-bottom: 2px solid #676767;
−
             /* margin: 0 2.4%; */
+
            margin-bottom: 20px;
 +
        }
 +
 
 +
        .h2 {
 +
            height: 40px;
 +
            line-height: 40px;
 +
            font-weight: bold;
 +
            height:auto;
 +
            /* font-weight: bold; */
 +
            font-family: 'Product Sans', sans-serif;
 +
            font-size: 30px;
 +
            color: #484848;
 +
             /* margin-bottom: 20px; */
 +
        }
 +
 
 +
        .h3 {
 +
            height: 30px;
 +
            line-height: 30px;
 +
            font-weight: bold;
 +
            height:auto;
 +
            /* font-weight: bold; */
 +
            font-family: 'Product Sans', sans-serif;
 +
            font-size: 24px;
 +
            color: #484848;
 +
            /* margin-bottom: 20px; */
 +
        }
 +
       
 +
        table {
 +
            color: #3B3B3B;
 
         }
 
         }
  
Line 434: Line 496:
  
 
         #float02 {}
 
         #float02 {}
−
 
−
        #float03 {}
 
  
 
         div.floatCtro {
 
         div.floatCtro {
 
             width: 100%;
 
             width: 100%;
−
             height: 250px;
+
             /* height: auto; */
 
             margin: 0;
 
             margin: 0;
 
             position: relative;
 
             position: relative;
Line 449: Line 509:
 
             display: block;
 
             display: block;
 
             width: 100%;
 
             width: 100%;
−
             height: 45px;
+
             /* height: auto; */
 +
            /* text-align: left !important; */
 
             color: #ffffff !important;
 
             color: #ffffff !important;
 
             font-size: 16px;
 
             font-size: 16px;
 +
            padding:0;
 
             background-color: #323643;
 
             background-color: #323643;
 
             border-bottom: 1px solid black;
 
             border-bottom: 1px solid black;
−
             /* border-radius: 5px; */
+
             padding:0 3%;
 
             text-decoration: none !important;
 
             text-decoration: none !important;
 
         }
 
         }
Line 460: Line 522:
 
         div.floatCtro .daohanger {
 
         div.floatCtro .daohanger {
 
             width: 100%;
 
             width: 100%;
−
             text-align: justify !important;
+
             text-align: left !important;
−
             height: 45px;
+
             height: auto;
−
             line-height: 45px;
+
             line-height: 25px;
 
             font-family: Arial;
 
             font-family: Arial;
−
             font-size: 14px;
+
             font-size: 14px !important;
 
             color: #676767;
 
             color: #676767;
 
             margin: 0;
 
             margin: 0;
−
             padding-left: 8%;
+
             padding:10px 8%;
 
             cursor: pointer;
 
             cursor: pointer;
 
             background: #fff;
 
             background: #fff;
Line 477: Line 539:
 
             width: 100%;
 
             width: 100%;
 
             height: 40px;
 
             height: 40px;
 +
            padding:10px 8%;
 
             /* margin: 10px 0 0 0; */
 
             /* margin: 10px 0 0 0; */
 
             background: #FFF;
 
             background: #FFF;
Line 486: Line 549:
 
         div.floatCtro a span {
 
         div.floatCtro a span {
 
             display: block;
 
             display: block;
−
             height: 44px;
+
             height: auto;
−
             line-height: 44px;
+
            text-align: left !important;
 +
             line-height: 18px;
 
             font-family: Arial;
 
             font-family: Arial;
 
             font-size: 16px;
 
             font-size: 16px;
−
            padding-left: 8%;
 
 
         }
 
         }
  
Line 515: Line 578:
  
 
         .biaoti {
 
         .biaoti {
−
             line-height: 40px;
+
             display: inline-block;
−
             width: 50%;
+
            margin: 8px 0;
−
             margin-left: 6%;
+
             /* width: 50%; */
−
             text-align: center;
+
             /* margin-left: 6%; */
 +
             /* text-align: center; */
 
             text-decoration: none !important;
 
             text-decoration: none !important;
 
         }
 
         }
Line 553: Line 617:
 
         }
 
         }
  
−
         @media screen and (max-width: 1000px) {             
+
         @media screen and (max-width: 1200px) {             
 
            
 
            
 +
            .cebian {
 +
            width: 15%;
 +
            }
 +
 +
            .zhengwen {
 +
            margin: 20px 20px 0 0;
 +
 
             .daohangyi {
 
             .daohangyi {
 
                 font-size: 14px;
 
                 font-size: 14px;
 
             }
 
             }
 +
            .daohangyi img {
 +
                display: none;
 +
            } 
 
         }
 
         }
  
−
         @media screen and (max-width: 880px) {
+
         @media screen and (max-width: 900px) {
  
 
             .daohangyi img {
 
             .daohangyi img {
Line 582: Line 656:
 
         <ul class="caidan">
 
         <ul class="caidan">
 
             <li class="hiLight shortName">
 
             <li class="hiLight shortName">
−
                 <a class="nav_head" href="#">
+
                 <a class="nav_head" href="https://2018.igem.org/Team:HZAU-China">
 
                     <span>Project</span>
 
                     <span>Project</span>
−
                     <span class="xjtPic"></span>
+
                     <span class="xsjPic"></span>
 
                 </a>
 
                 </a>
 
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Description">Description</a>
 
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Description">Description</a>
Line 598: Line 672:
 
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Experiments">Experiments</a>
 
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Experiments">Experiments</a>
 
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Improve">Improve</a>
 
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Improve">Improve</a>
−
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/InterLab">Interlab</a>
+
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/InterLab">InterLab</a>
 +
                <a class="item" href="https://2018.igem.org/Team:HZAU-China/Notebook">Notebook</a>
 +
 
 
             </li>
 
             </li>
 
             <li class="hiLight shortName">
 
             <li class="hiLight shortName">
Line 613: Line 689:
 
                     <span class="xjtPic"></span>
 
                     <span class="xjtPic"></span>
 
                 </a>
 
                 </a>
−
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Safety">Safty</a>
+
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Safety">Safety</a>
 
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Human_Practices">Human Practices</a>
 
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Human_Practices">Human Practices</a>
 
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Public_Engagement">Public Engagement</a>
 
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Public_Engagement">Public Engagement</a>
Line 626: Line 702:
 
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Collaborations">Collaborations</a>
 
                 <a class="item" href="https://2018.igem.org/Team:HZAU-China/Collaborations">Collaborations</a>
 
             </li>
 
             </li>
−
             <li class="shortName">
+
             <li class="hiLight shortName">
−
                 <a class="nav_head" href="https://2018.igem.org/Team:HZAU-China/Parts">
+
                 <a class="nav_head" href="#">
 
                     <span>Parts</span>
 
                     <span>Parts</span>
 +
                    <span class="xjtPic"></span>
 
                 </a>
 
                 </a>
 +
                <a class="item" href="https://2018.igem.org/Team:HZAU-China/Basic_Part">Basic</a>
 +
                <a class="item" href="https://2018.igem.org/Team:HZAU-China/Composite_Part">Composite</a>
 
             </li>
 
             </li>
 
         </ul>
 
         </ul>
Line 638: Line 717:
 
         <!-- 正文 -->
 
         <!-- 正文 -->
 
         <div class="zhengwen">
 
         <div class="zhengwen">
−
            <img class="daimg" src="https://static.igem.org/mediawiki/2018/7/70/T--HZAU-China--hezhao1.png" alt="">
 
 
             <div id="float01" class="cur">
 
             <div id="float01" class="cur">
−
                 <div class="h1">biaotiyi</div>
+
                 <div class="h1">Collaboration with WHU-China
 +
                    and SDU-CHINA</div>
 +
                <p>Optogenetic tool has broad prospects on synthetic biology, and the CcaS-CcaR system, which is
 +
                    developed from <i>cyanobacteria</i> has made obvious achievements, thus more and more teams are
 +
                    willing to
 +
                    use this system in their own projects. In the past two years, we have spent a great deal of time
 +
                    using it in our projects and accumulated a lot of experience (see more information in our previous
 +
                    wikis). This year, we collaborated with WHU-China and SDU-CHINA who use this system in their projects and
 +
                    sharing the experience how we regulated the expression of CcaS and CcaR protein to control this
 +
                    optogenetic tool and what we achieved.
 +
                </p>
 +
 
 +
                <div class="row">
 +
                    <div class="col-xs-6 col-sm-6 col-md-6 col-lg-6">
 +
                        <div style="width: 60%; margin: 30px auto">
 +
                            <a href="https://2018.igem.org/Team:WHU-China/Collaborations"><img src="https://static.igem.org/mediawiki/2018/9/9a/T--WHU-China--wiki-Collabration_whu.png"
 +
                                    width=100% alt=""></a>
 +
                        </div>
 +
                    </div>
 +
                    <div class="col-xs-6 col-sm-6 col-md-6 col-lg-6">
 +
                        <div style="width: 60%; margin: 30px auto">
 +
                            <a href="https://2018.igem.org/Team:SDU-CHINA/Collaborations"><img src="https://static.igem.org/mediawiki/2018/c/c5/T--HZAU-China--SDU.png"
 +
                                    width=100% alt=""></a>
 +
                        </div>
 +
                    </div>
 +
                </div>
  
 
             </div>
 
             </div>
 
             <div id="float02">
 
             <div id="float02">
−
                 <div class="h1">biaotier</div>
+
                 <div class="h1">Experience sharing with Worldshaper-Wuhan</div>
 +
                <p>We cooperated with the high school team, Worldshaper-Wuhan. We shared some information about our
 +
                    project and had several
 +
                    discussions then determined to have an experiment about the lncRNA IL7-AS in multiple cell lines.
 +
                    LncRNA IL7-AS is a newly discovered lncRNA, which might be a potential diagnostic biomarker and
 +
                    therapeutic target for renal cell carcinoma. Through this experiment, firstly, we want to know if
 +
                    the IL7-AS has tissue specificity to distinguish between cancer cells and healthy cells or not.
 +
                    Secondly, we want to explore its applicability for which this biomarker can be widely utilized to
 +
                    detect tumours. The Worldshaper-Wuhan team successfully demonstrated that IL7-AS has specificity and
 +
                    universality. There were significant expression differences among 293T (the healthy cell), 769-P
 +
                    (the adenocarcinoma cell) and 786-O (the adenocarcinoma cell) cell lines. The expression in 769-P
 +
                    and 786-O were higher than that of 293T, showing specificity and universality of IL7-AS. Through our
 +
                    team's suggestions and Worldshaper-Wuhan's experiment, their project improved and we also got a new
 +
                    biomarker
 +
                    and therapeutic target for future projects.
 +
                </p>
 +
                <div style="width: 20%; margin: 30px auto">
 +
                    <a href="https://2018.igem.org/Team:Worldshaper-Wuhan/Collaborations"><img src="https://static.igem.org/mediawiki/2018/b/b6/T--HZAU-China--WSWH.png"
 +
                            width=100% alt=""></a>
 +
                </div>
 +
 
 +
                <div class="row">
 +
                    <div class="col-xs-6 col-sm-6 col-md-4 col-lg-4">
 +
                        <div style="width: 100%; margin: 30px auto; border:8px solid #E0CCAE; box-shadow: 0 1px 3px #676767; ">
 +
                            <img src="https://static.igem.org/mediawiki/2018/0/02/T--HZAU-China--WSWH1.png" width=100% alt="">
 +
                        </div>
 +
                    </div>
 +
                    <div class="col-xs-6 col-sm-6 col-md-4 col-lg-4">
 +
                        <div style="width: 100%; margin: 30px auto; border:8px solid #E0CCAE; box-shadow: 0 1px 3px #676767;">
 +
                            <img src="https://static.igem.org/mediawiki/2018/9/97/T--HZAU-China--WSWH2.png" width=100% alt="">
 +
                        </div>
 +
                    </div>
 +
                    <div class="col-xs-6 col-sm-6 col-md-4 col-lg-4">
 +
                        <div style="width: 100%; margin: 30px auto; border:8px solid #E0CCAE; box-shadow: 0 1px 3px #676767;">
 +
                            <img src="https://static.igem.org/mediawiki/2018/3/35/T--HZAU-China--WSWH3.png" width=100% alt="">
 +
                        </div>
 +
                    </div>
 +
                </div>
 +
 
  
 
             </div>
 
             </div>
 
             <div id="float03">
 
             <div id="float03">
−
                 <div class="h1">biaotisan</div>
+
                 <div class="h1">Help from NAU-CHINA</div>
−
                  
+
 
 +
                 <div class="row">
 +
                    <div class="col-xs-6 col-sm-6 col-md-6 col-lg-6">
 +
                        <div style="width: 100%; margin: 30px auto; padding: 0 20px;">
 +
                            <p>After the information we got from meetings and public investigation, we thought it’s
 +
                                necessary to
 +
                                enhance the targeting of engineered <i>Salmonella</i> we used, we designed a fuse
 +
                                protein which
 +
                                called OmpA-RGD to achieve
 +
                                this goal. RGD is a well-studied tumor homing tripeptide that specifically binds to
 +
                                alpha v beta 3
 +
                                (αvβ3) integrin, which is widely overexpressed on cancer cells. So there’s a cell line
 +
                                called
 +
                                MDA-MB-231 surface displaying αvβ3 needed for our further targeting and safety
 +
                                experiments, with
 +
                                the great help of NAU-CHINA , we had channels to get this cell line from Shanghai
 +
                                Institute of
 +
                                Biochemistry and Cell Biology.
 +
                            </p>
 +
                        </div>
 +
                    </div>
 +
                    <div class="col-xs-6 col-sm-6 col-md-6 col-lg-6">
 +
                        <div style="width: 80%; margin: 30px auto; ">
 +
                            <a href="https://2018.igem.org/Team:NAU-CHINA/Collaborations"><img src="https://static.igem.org/mediawiki/2018/8/88/T--HZAU-China--NAU.png"
 +
                                    width=100% alt=""></a>
 +
                        </div>
 +
                    </div>
 +
                </div>
 +
 
 +
                <div class="h1">Collaboration with HUST-China</div>
 +
                <p>When we submitted our parts, we got the help of HUST-China. HUST-China
 +
                    helped us freeze the plasmid into dry powder in 96 well plate format, label our plate with our team name and
 +
                    submission number, and eventually send it by express to the agency in China. We are extremely grateful for their help.
 +
                </p>
 +
 
 +
                <div class="row">
 +
                    <div class="col-xs-6 col-sm-6 col-md-6 col-lg-6">
 +
                        <div style="width: 100%; margin: 30px auto; box-shadow: 0 1px 3px #676767; background-color: #333333; ">
 +
                            <a href="https://2018.igem.org/Team:HUST-China/Collaborations"><img src="https://static.igem.org/mediawiki/2018/6/6e/T--HZAU-China--HUST1.jpg"
 +
                                    width=100% alt=""></a>
 +
                        </div>
 +
                    </div>
 +
                    <div class="col-xs-6 col-sm-6 col-md-6 col-lg-6">
 +
                        <div style="width: 100%; margin: 30px auto; border:8px solid #E0CCAE; box-shadow: 0 1px 3px #676767; ">
 +
                            <img src="https://static.igem.org/mediawiki/2018/0/06/T--HZAU-China--HUST.jpg" width=100% alt="">
 +
                        </div>
 +
                    </div>
 +
 
 +
                </div>
 +
 
 +
                <div class="h1">EurAisan Meetup</div>
 +
                <p>We also took part in the iGEM EurAisan Meetup, where we shared our ideas and learned a lot. At the
 +
                    meeting, we had friendly communications with many iGEMers and gained a lot of advice during this
 +
                    meetup. They suggested more possible delivery vehicles to our project and a more logical poster
 +
                    design. We took part in a quiz competition and were awarded the prize for best collaboration quiz
 +
                    with our buddy team SFLS_Shenzhen. After the meetup, we're still talking on WeChat.
 +
                </p>
 +
 
 +
                <div class="row">
 +
                    <div class="col-xs-6 col-sm-6 col-md-6 col-lg-6">
 +
                        <div style="width: 100%; margin: 30px auto; border:8px solid #E0CCAE; box-shadow: 0 1px 3px #676767; ">
 +
                            <img src="https://static.igem.org/mediawiki/2018/8/82/T--HZAU-China--OUYA1.jpg" width=100% alt="">
 +
                        </div>
 +
                    </div>
 +
                    <div class="col-xs-6 col-sm-6 col-md-6 col-lg-6">
 +
                        <div style="width: 100%; margin: 30px auto; border:8px solid #E0CCAE; box-shadow: 0 1px 3px #676767;">
 +
                            <img src="https://static.igem.org/mediawiki/2018/a/ac/T--HZAU-China--OUYA2.jpg" width=100% alt="">
 +
                        </div>
 +
                    </div>
 +
                </div>
 +
 
 +
                <div class="h1">CCiC meeting</div>
 +
                <p>In August, we participated in the biggest iGEMer communication conference in China——Conference of
 +
                    China iGEMer Community (CCiC). During this meeting, we communicated with teams tracking on therapy and reflected more about our project. For further collaboration，we met the captain of WHU-China and
 +
                    talked about the experience of our optogenetic tool.</p>
 +
 
 +
 
 +
                <div class="row">
 +
                    <div class="col-xs-6 col-sm-6 col-md-6 col-lg-6">
 +
                        <div style="width: 100%; margin: 30px auto; border:8px solid #E0CCAE; box-shadow: 0 1px 3px #676767; ">
 +
                            <img src="https://static.igem.org/mediawiki/2018/e/e0/T--HZAU-China--CCiC1.jpg" width=100% alt="">
 +
                        </div>
 +
                        <div style="width: 100%; margin: 30px auto; border:8px solid #E0CCAE; box-shadow: 0 1px 3px #676767;">
 +
                            <img src="https://static.igem.org/mediawiki/2018/4/47/T--HZAU-China--CCiC2.jpg" width=100% alt="">
 +
                        </div>
 +
                    </div>
 +
                    <div class="col-xs-6 col-sm-6 col-md-6 col-lg-6">
 +
                        <div style="width: 100%; margin: 30px auto; border:8px solid #E0CCAE; box-shadow: 0 1px 3px #676767;">
 +
                            <img src="https://static.igem.org/mediawiki/2018/3/32/T--HZAU-China--CCiC3.jpg" width=100% alt="">
 +
                        </div>
 +
                    </div>
 +
                </div>
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 +
 
 
             </div>
 
             </div>
 
         </div>
 
         </div>
Line 664: Line 903:
 
             </a>
 
             </a>
 
             <div class="daohangyi">
 
             <div class="daohangyi">
−
                    <span class="biaoti">Collaborations</span>
+
                <span class="biaoti">Collaborations</span>
−
                    <span class="xsjPic"><img src="https://static.igem.org/mediawiki/2018/8/8d/T--HZAU-China--xjt.svg" alt=""></span>
+
                <span class="xsjPic"><img src="https://static.igem.org/mediawiki/2018/8/8d/T--HZAU-China--xjt.svg" alt=""></span>
−
                </div>
+
            </div>
 
             <div class="floatCtro">
 
             <div class="floatCtro">
−
                 <p class="daohanger">neirongyi</p>
+
                 <!-- <p class="daohanger">Project Support</p>
−
                 <p class="daohanger">neironger</p>
+
                 <p class="daohanger">Experience Sharing</p>
−
                 <p class="daohanger">neirongsan</p>
+
                 <p class="daohanger">neirongsan</p> -->
 
                 <a>
 
                 <a>
 
                     <span>Back&nbsp;to&nbsp;Top</span>
 
                     <span>Back&nbsp;to&nbsp;Top</span>
Line 733: Line 972:
  
 
</html>
 
</html>
−
 
−
<!-- {{HZAU-China}}
 
−
<html>
 
−
 
−
 
−
 
−
<div class="column full_size judges-will-not-evaluate">
 
−
<h3>★  ALERT! </h3>
 
−
<p>This page is used by the judges to evaluate your team for the <a href="https://2018.igem.org/Judging/Medals">medal criterion</a> or <a href="https://2018.igem.org/Judging/Awards"> award listed below</a>. </p>
 
−
<p> Delete this box in order to be evaluated for this medal criterion and/or award. See more information at <a href="https://2018.igem.org/Judging/Pages_for_Awards"> Instructions for Pages for awards</a>.</p>
 
−
</div>
 
−
 
−
 
−
<div class="clear"></div>
 
−
 
−
 
−
<div class="column full_size">
 
−
<h1>Collaborations</h1>
 
−
 
−
<p>
 
−
Sharing and collaboration are core values of iGEM. We encourage you to reach out and work with other teams on difficult problems that you can more easily solve together.
 
−
</p>
 
−
 
−
<h3>Silver Medal Criterion #2</h3>
 
−
<p>
 
−
Complete this page if you intend to compete for the silver medal criterion #2 on collaboration. Please see the <a href="https://2018.igem.org/Judging/Medals">2018 Medals Page</a> for more information.
 
−
</p>
 
−
</div>
 
−
 
−
<div class="column two_thirds_size">
 
−
 
−
<h4> Which other teams can we work with? </h4>
 
−
<p>
 
−
You can work with any other team in the competition, including software, hardware, high school and other tracks. You can also work with non-iGEM research groups, but they do not count towards the iGEM team collaboration silver medal criterion.
 
−
</p>
 
−
 
−
<p>
 
−
In order to meet the silver medal criteria on helping another team, you must complete this page and detail the nature of your collaboration with another iGEM team.
 
−
</p>
 
−
 
−
</div>
 
−
 
−
 
−
 
−
<div class="column third_size">
 
−
<p>
 
−
Here are some suggestions for projects you could work on with other teams:
 
−
</p>
 
−
 
−
<ul>
 
−
<li> Improve the function of another team's BioBrick Part or Device</li>
 
−
<li> Characterize another team's part </li>
 
−
<li> Debug a construct </li>
 
−
<li> Model or simulate another team's system </li>
 
−
<li> Test another team's software</li>
 
−
<li> Help build and test another team's hardware project</li>
 
−
<li> Mentor a high-school team</li>
 
−
</ul>
 
−
</div>
 
−
 
−
 
−
</html> -->
 

Latest revision as of 20:37, 17 October 2018

Collaboration with WHU-China and SDU-CHINA

Optogenetic tool has broad prospects on synthetic biology, and the CcaS-CcaR system, which is developed from cyanobacteria has made obvious achievements, thus more and more teams are willing to use this system in their own projects. In the past two years, we have spent a great deal of time using it in our projects and accumulated a lot of experience (see more information in our previous wikis). This year, we collaborated with WHU-China and SDU-CHINA who use this system in their projects and sharing the experience how we regulated the expression of CcaS and CcaR protein to control this optogenetic tool and what we achieved.

Experience sharing with Worldshaper-Wuhan

We cooperated with the high school team, Worldshaper-Wuhan. We shared some information about our project and had several discussions then determined to have an experiment about the lncRNA IL7-AS in multiple cell lines. LncRNA IL7-AS is a newly discovered lncRNA, which might be a potential diagnostic biomarker and therapeutic target for renal cell carcinoma. Through this experiment, firstly, we want to know if the IL7-AS has tissue specificity to distinguish between cancer cells and healthy cells or not. Secondly, we want to explore its applicability for which this biomarker can be widely utilized to detect tumours. The Worldshaper-Wuhan team successfully demonstrated that IL7-AS has specificity and universality. There were significant expression differences among 293T (the healthy cell), 769-P (the adenocarcinoma cell) and 786-O (the adenocarcinoma cell) cell lines. The expression in 769-P and 786-O were higher than that of 293T, showing specificity and universality of IL7-AS. Through our team's suggestions and Worldshaper-Wuhan's experiment, their project improved and we also got a new biomarker and therapeutic target for future projects.

Help from NAU-CHINA

After the information we got from meetings and public investigation, we thought it’s necessary to enhance the targeting of engineered Salmonella we used, we designed a fuse protein which called OmpA-RGD to achieve this goal. RGD is a well-studied tumor homing tripeptide that specifically binds to alpha v beta 3 (αvβ3) integrin, which is widely overexpressed on cancer cells. So there’s a cell line called MDA-MB-231 surface displaying αvβ3 needed for our further targeting and safety experiments, with the great help of NAU-CHINA , we had channels to get this cell line from Shanghai Institute of Biochemistry and Cell Biology.

Collaboration with HUST-China

When we submitted our parts, we got the help of HUST-China. HUST-China helped us freeze the plasmid into dry powder in 96 well plate format, label our plate with our team name and submission number, and eventually send it by express to the agency in China. We are extremely grateful for their help.

EurAisan Meetup

We also took part in the iGEM EurAisan Meetup, where we shared our ideas and learned a lot. At the meeting, we had friendly communications with many iGEMers and gained a lot of advice during this meetup. They suggested more possible delivery vehicles to our project and a more logical poster design. We took part in a quiz competition and were awarded the prize for best collaboration quiz with our buddy team SFLS_Shenzhen. After the meetup, we're still talking on WeChat.

CCiC meeting

In August, we participated in the biggest iGEMer communication conference in China——Conference of China iGEMer Community (CCiC). During this meeting, we communicated with teams tracking on therapy and reflected more about our project. For further collaboration，we met the captain of WHU-China and talked about the experience of our optogenetic tool.

Team Attributions
Collaborations
Back to Top